CN102327369B - Pharmaceutical composition and medicine for treating hepatic injury, and preparation method thereof - Google Patents
Pharmaceutical composition and medicine for treating hepatic injury, and preparation method thereof Download PDFInfo
- Publication number
- CN102327369B CN102327369B CN201110309035.XA CN201110309035A CN102327369B CN 102327369 B CN102327369 B CN 102327369B CN 201110309035 A CN201110309035 A CN 201110309035A CN 102327369 B CN102327369 B CN 102327369B
- Authority
- CN
- China
- Prior art keywords
- preparation
- medicine
- pharmaceutical composition
- parts
- hepatic injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition and medicine for treating hepatic injury, and a preparation method thereof. The composition is prepared from the following active pharmaceutical ingredients in parts by weight: 5-10 parts of picrorhiza rhizome, 5-10 parts of safflower, 1-5 parts of Tibetan capillaris, 1-5 parts of sophora moorcroftiana seed and 1-5 parts of myrobalam. The extracts of the active pharmaceutical ingredients and pharmaceutically acceptable assistant ingredients can form a corresponding oral preparation. The pharmaceutical composition is used for treating chemical hepatic injury, pathological hepatic injury and hepatic injury caused by many other reasons, and can have an ideal effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and corresponding medicine and preparation method thereof for the treatment of hepatic injury.
Background technology
Liver is metabolism organ and the secretory that body weight for humans is wanted, and is also fragile internal organs in powerful, is easy to cause hepatic injury.The reason of hepatic injury mainly comprises violence nature hepatic injury, pathologic hepatic injury, chemical liver injury etc.Wherein violence nature hepatic injury multilist is now obviously quick, and serious; And pathologic hepatic injury and chemical liver injury are the most common.No matter be integrated environment or people's life style at present, all totally unfavorable to the health of liver, cause the factor of hepatic injury extensively to exist, be the major reason that causes hepatic injury crowd quantity to expand rapidly.As the overwork of staying up late can cause liver blood flow relative deficiency, the nutrition that affects liver cell is moistened, and resistance declines, and causes hepatocyte in damaged condition to be difficult to repair and exacerbated; Drinking too much can directly be poisoned hepatocyte, affects its structure and function; Environmental pollution makes various chemical toxicants enter human body, understands unavoidably liver injury; Fatty liver and alcoholic liver all can cause hepatic injury, worsen development if let alone, and finally can change liver cirrhosis into, even worsen as hepatocarcinoma.
In addition, have been reported nearly 1000 kinds of medicines and can cause hepatic disease, severe patient can cause liver failure, needs liver transplantation, and even dead, drug induced hepatic injury has become doctor, health agency and the challenging research topic of drugmaker's staying quality.
Summary of the invention
For above-mentioned situation, first the present invention will provide a kind of pharmaceutical composition for the treatment of hepatic injury, and the medicine of the treatment hepatic injury take said composition as effective ingredient is further provided, and the preparation method of this pharmaceutical composition.
The present invention treats the pharmaceutical composition of hepatic injury, take the active drug composition raw material of weight portion as:
Rhizoma Picrorhizae 5-10 part, Flos Carthami 5-10 part, ZANGYINCHEN 1-5 part,
The sub-1-5 part of Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae 1-5 part.
Anti-liver injury pharmacodynamic study and clinical trial show, pharmaceutical composition of the present invention is in scope described above, carry out increase and decrease and the adjustment of corresponding proportion or dosage, do not affect the beneficial effect of the present composition, all there is good the liver protecting and ALT lowering and anti-liver injury effect.
The further preferred group of above-mentioned active drug composition raw material becomes:
6 parts of Rhizoma Picrorhizae, 6 parts, Flos Carthami, 4.5 parts of ZANGYINCHEN,
3 parts of 1.5 parts of Fructus Chebulaes of Sophora moocroftiana(Wall．) Benth. Ex Bak..
Said each active drug composition in aforementioned pharmaceutical compositions of the present invention, though do not get rid of directly directly to form or use with the form (as forms such as powder) of each ingredient raw material and can obtain same effect yet, but for reducing the waste of medicinal raw material, improve the utilization rate of medical material, and facilitate patient to use and improve curative effect, modern Chinese medicine does not generally advocate to be directly used as medicine with medical material powder etc.Therefore, aforementioned pharmaceutical compositions of the present invention is preferably by water and/or the ethanol extraction of said each active drug composition raw material and forms.
The preparation of aforementioned pharmaceutical compositions of the present invention, can adopt any in following manner:
Method one: after the Rhizoma Picrorhizae in said raw material, ZANGYINCHEN, Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae are pulverized, filter after extracting with the alcoholic solution of volumetric concentration 50% ~ 80%, filtrate is removed ethanol and is condensed into extractum, mixes with the water extraction concentrate of Flos Carthami, or further dry.
Wherein, said ethanol extraction is preferably respectively with the said alcoholic solution reflux, extract, of 6 ~ 12 times at least 2 times, each 1 ~ 2 hour, merges the extracting solution of each time.
Said crude extract from carthamus tinctorius L. with water, is preferably and uses respectively 40 ℃ ~ 70 ℃ warm macerating of water of 10 ~ 20 times to extract at least 2 times.
Method two: after the Rhizoma Picrorhizae in said raw material, ZANGYINCHEN, Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae are pulverized, the alcoholic solution that is 50% ~ 80% by volumetric concentration in the lump with Flos Carthami extracts rear filtration, and filtrate is removed ethanol and is condensed into extractum, or further dry.Extracting method can be undertaken by the ethanol extraction mode in method one.
Method three: mix with Flos Carthami after the Rhizoma Picrorhizae in said raw material, ZANGYINCHEN, Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae are pulverized, add respectively 10 ~ 15 times of water and at least decoct 2 times, each 1 ~ 2 hour, filter merging filtrate concentrate drying.
The analysis and research of effective ingredient show, the main effective ingredient of the liver protecting and ALT lowering in the raw material such as the Rhizoma Picrorhizae of aforementioned pharmaceutical compositions of the present invention, Flos Carthami, ZANGYINCHEN, Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae, all soluble in water or moisture alcoholic solution.Further the liver protecting and ALT lowering test of pesticide effectiveness result also shows, the said pharmaceutical composition of the present invention adopts the extract being obtained by above-mentioned water and/or 50 ~ 80% ethanol to form, and all can have good anti-liver injury drug action.
Take above-mentioned pharmaceutical composition as effective ingredient, with acceptable auxiliary element in medicine, according at present corresponding conventional method and technique, can form or prepare the medicine of corresponding operational treatment hepatic injury.For example, can preferably be prepared into the medicine of the peroral dosage forms such as capsule easy to use, tablet, granule or pill.
Aforementioned pharmaceutical compositions of the present invention and the pharmaceutical preparation take it as active drug composition, take Tibetan medicine genuine medicinal materials Rhizoma Picrorhizae, ZANGYINCHEN etc. as main component, the Modern Tibetan compound medicine thing of compatibility composition control hepatic injury, show to have good control hepatic injury effect through clinical practice, clinical efficacy is definite, the pure Tibetan medicinal preparation that side effect is little and price is suitable, has broad application prospects and practical value.
The specific embodiment is by the following examples described in further detail foregoing of the present invention again.But the scope that should not be construed as the above-mentioned theme of the present invention only limits to following example.Without departing from the idea case in the present invention described above, various replacements or the change made according to ordinary skill knowledge and customary means, all should comprise within the scope of the invention.
The specific embodiment
embodiment 1
Get Rhizoma Picrorhizae 600g, ZANGYINCHEN 450g, the sub-150g of Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae 300g, be ground into coarse powder, add 70% alcohol reflux 2 times, add for the first time 10 times of amounts, add for the second time 8 times of amounts, reflux 1～2 hour at every turn, filter, merging filtrate, decompression recycling ethanol, concentrated, extractum is for subsequent use.Separately get Flos Carthami 600g and add water and be heated to approximately 60 ℃ of warm macerating and extract 2 times, add water for the first time 15 times, add water for the second time 12 times, each dynamic agitation is extracted 0.5～1 hour, filters merging filtrate, reclaim under reduced pressure is concentrated, adds above-mentioned extractum, continues to be concentrated into relative density and is about 1.25～1.35, drying under reduced pressure, pulverized 60 mesh sieves, added right amount of auxiliary materials, mix homogeneously, processed according to a conventional method, incapsulates and get final product.
embodiment 2
Get Rhizoma Picrorhizae 1000g, ZANGYINCHEN 400g, the sub-300g of Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae 500g, pulverize, add Flos Carthami 500g, add 60% alcohol reflux 2 times, add for the first time 12 times of amounts, add for the second time 10 times of amounts, each backflow 1～2 hour, filters merging filtrate, decompression recycling ethanol, be concentrated into thick paste, microwave decompression dry, pulverize, add right amount of auxiliary materials, mix homogeneously, according to a conventional method processed, tabletting, coating and get final product.
embodiment 3
Get Rhizoma Picrorhizae 1000g, ZANGYINCHEN 500g, the sub-500g of Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae 500g, pulverize, add Flos Carthami 1000g, decoct with water and extract 2 times, add water for the first time 14 times, add water for the second time 12 times, each decoction 1～2 hour, filters merging filtrate, concentrating under reduced pressure, dry, pulverize, add right amount of auxiliary materials, mix homogeneously, processed according to a conventional method, incapsulates and get final product.
embodiment 4
Get Rhizoma Picrorhizae 500g, ZANGYINCHEN 100g, the sub-100g of Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae 100g, pulverize, add 50% alcohol reflux 2 times, add for the first time 10 times of amounts, add for the second time 8 times of amounts, reflux 1～2 hour at every turn, filter, merging filtrate, decompression recycling ethanol, concentrated, extractum is for subsequent use.Separately get Flos Carthami 500g and add water and be heated to approximately 50 ℃ of warm macerating and extract 2 times, add water for the first time 18 times, add water for the second time 15 times, each dynamic agitation is extracted 0.5～1 hour, filters merging filtrate, reclaim under reduced pressure is concentrated, add above-mentioned extractum, continue concentrated, dry, add right amount of auxiliary materials, mix homogeneously, processed according to a conventional method, granulation agent and get final product.
Carry out following pharmacodynamic experiment research with the above-mentioned drug combination preparation of the present invention, further proved the beneficial effect that drug combination preparation of the present invention has.
Medicine of the present invention: the suspension that the pharmaceutical composition of embodiment 1 is made into desired concn with distilled water is for subsequent use, this test is pressed crude drug in whole g/kg and is calculated.
Control drug: Bicyclol (lot number is 090307, is produced by Beijing XieHe medicine Factory for the accurate word H20040467 of traditional Chinese medicines, 25mg/ sheet), is made into the suspension of desired concn with 0.5CMC for subsequent use before use.
1, carbon tetrachloride is caused to acute liver protective effect
50 of male mices getting body weight and be 20-22g, are divided into 5 groups at random, gavage compound recipe Rhizoma Picrorhizae 8.4g/kg, 25.2g/kg respectively, bicyclol 100mg/kg, and equivalent 0.5%CMC, every day twice, continuous 5 times, after last administration 1 hour, lumbar injection CCl
413 μ l/kg, and fasting can't help water after 16 hours, gets hematometry Serum ALT, AST activity, the results are shown in Table 1.
Table 1 causes the impact (x ± s) of acute liver on carbon tetrachloride
| Group | Dosage (g/kg) | Number of animals | ALT（U/L） | AST（U/L） |
| Contrast | ? | 10 | 45.6±9.6 *** | 90.0±13.7 *** |
| Model | ? | 10 | 192.7±31.7 | 134.3±21.1 |
| Medicine of the present invention | 8.4 | 10 | 141.9±29.1 ** | 124.5±31.2 |
| Medicine of the present invention | 25.2 | 10 | 130.9±33.9 ** | 117.2±20.4 |
| Bicyclol | 0.1 | 10 | 78.0±37.3 *** | 130.3±30.7 |
With model group comparison:
*p<0.05,
*p<0.01,
* *p<0.001.
As seen from Table 1: carbon tetrachloride can cause that mice serum transaminase activity obviously raises, and relatively has significant difference with matched group.The each dosage group of compound recipe Rhizoma Picrorhizae can significantly reduce carbon tetrachloride mice serum ALT activity, relatively has significant difference with model group.
2, thioacetamide (TAA) is caused the impact of acute liver
Getting body weight is 18 ~ 22g male mice, is divided at random matched group, model group, compound recipe Rhizoma Picrorhizae 2.5g/kg, compound recipe Rhizoma Picrorhizae 5g/kg, compound recipe Rhizoma Picrorhizae 10.0g/kg, bicyclol 100mg/kg.Every day gastric infusion 2 times, continuous 5 times, matched group and model group give equal-volume 0.5%CMC-Na liquid, after last administration one hour, except matched group, the equal lumbar injection thioacetamides of all the other each treated animals (TAA) 50mg/kg, and 16 hours collection blood of water is can't help in fasting after modeling, standing centrifugal, get determination of serum ALT, AST activity, the results are shown in Table 2.
Table 2 compound recipe Rhizoma Picrorhizae causes the impact (x ± s) of hepatic injury mice serum transaminase activity on TAA
| Group | Dosage (g/kg) | N | ALT(U/L) | AST(U/L) |
| Contrast | ? | 10 | 45.9±6.5 *** | 138.8±19.4 *** |
| Model | ? | 11 | 200.7±86.7 | 213.6±54.3 |
| Medicine of the present invention | 2.5 | 10 | 184.8±46.1 | 233.0±25.2 |
| Medicine of the present invention | 5.0 | 11 | 141.1±40.4 | 196.3±26.5 |
| Medicine of the present invention | 10.0 | 11 | 133.7±40.7 * | 224.2±49.6 |
| Bicyclol | 0.1 | 10 | 48.4±13.2 *** | 187.7±47.9 |
With model group comparison:
* p<0.05, * * p<0.001.
As seen from Table 2, thioacetamide can cause the active obviously rising of mice serum ALT, AST, relatively has significant difference with matched group.Compound recipe Rhizoma Picrorhizae and bicyclol can significantly reduce TAA mice serum ALT level, relatively have significant difference with model group.
3, acetaminophen causes the impact of the explosive hepatic necrosis model of mice
Getting body weight is 18 ~ 22g male mice, is divided at random matched group, model group, compound recipe Rhizoma Picrorhizae 2.5g/kg, compound recipe Rhizoma Picrorhizae 5g/kg, compound recipe Rhizoma Picrorhizae 10.0g/kg, bicyclol 100mg/kg.Every day gastric infusion 2 times, continuous 5 times, matched group and model group give equal-volume 0.5%CMC-Na liquid, after last administration one hour, except matched group, the equal lumbar injection acetaminophen of all the other each treated animals (APAP) 650mg/kg, observes and records the death condition of each treated animal in modeling 72 hours.Result X
2check, in table 3.
Table 3 compound recipe Rhizoma Picrorhizae causes the impact of the explosive hepatic necrosis of mice on acetaminophen
| Group | Dosage (g/kg) | Number of animals | Dead animal number | Mortality rate (%) |
| Model | ? | 14 | 13 | 92.9 |
| Medicine of the present invention | 2.5 | 14 | 6 | 42.9 * |
| Medicine of the present invention | 5.0 | 14 | 2 | 14.3 *** |
| Medicine of the present invention | 10.0 | 14 | 1 | 7.1 *** |
| Bicyclol | 0.1 | 14 | 2 | 14.3 *** |
With model group comparison:
* p<0.05, * p<0.01, * * p<0.001.
As seen from Table 3: the acetaminophen of lumbar injection heavy dose can cause that 92.9% mice is dead in 72 hours.Each medicine group all can significantly reduce acetaminophen is caused to dead mouse quantity and mortality rate, relatively has significant difference with model group.
4, to canavalinea(
con A) cause the impact of acute liver
Getting body weight is 18 ~ 22g male mice, is divided at random matched group, model group, compound recipe Rhizoma Picrorhizae 2.5g/kg, compound recipe Rhizoma Picrorhizae 5g/kg, compound recipe Rhizoma Picrorhizae 10.0g/kg, bicyclol 100mg/kg.Every day gastric infusion 2 times, continuous 5 times, matched group and model group give equal-volume 0.5%CMC-Na liquid, after last administration one hour, except matched group, equal lumbar injection ConA 28 mg/kg of all the other each treated animals, matched group gives isopyknic normal saline.And fasting be can't help water and is collected blood after 16 hours after modeling, leave standstill centrifugally, get serum and survey ALT, AST activity.Get liver organization is placed in 10% formalin and does histopathology microscopy after fixing simultaneously.The results are shown in Table 4.
As seen from Table 4, Con A can cause the active obviously rising of mice serum ALT, AST, relatively has significant difference with matched group.The each dosage group of compound recipe Rhizoma Picrorhizae and bicyclol can significantly reduce Con A mice serum ALT level, relatively have significant difference with model group, and compound recipe Rhizoma Picrorhizae also has the trend that reduces AST level, but a little less than effect, with relatively no difference of science of statistics of model group.
Table 4 compound recipe Rhizoma Picrorhizae causes the impact (x ± s) of hepatic injury mice serum transaminase activity on ConA
| Group | Dosage (g/kg) | ? | N | ALT（U/L） | ? | AST（U/L） |
| Contrast | ? | ? | 13 | 40.9±23.5 *** | ? | 115.7±23.1 *** |
| Model | ? | ? | 13 | 462.8±204.9 | ? | 372.8±83.7 |
| Medicine of the present invention | 2.5 | ? | 10 | 226.8±170.2 ** | ? | 302.0±97.2 |
| Medicine of the present invention | 5.0 | ? | 11 | 369.9±159.0 | ? | 388.7±87.2 |
| Medicine of the present invention | 10.0 | ? | 12 | 185.5±166.2 ** | ? | 298.9±106.8 |
| Bicyclol | 0.1 | ? | 13 | 190.9±148.5 *** | ? | 355.5±115.6 |
With model group comparison:
* p<0.05, * p<0.01, * * p<0.001.
5, isothiocyanate 1-naphthyl ester is caused the impact of rat jaundice liver damage model
Getting body weight is 180 ~ 230g male rat, is divided at random matched group, model group, compound recipe Rhizoma Picrorhizae 2.5g/kg, compound recipe Rhizoma Picrorhizae 5g/kg, compound recipe Rhizoma Picrorhizae 10.0g/kg, bicyclol 100mg/kg.Every day gastric infusion 2 times, continuous 5 times, matched group and model group give equal-volume 0.5%CMC-Na liquid, in administration 2 times fasting after 24 hours, lumbar injection isothiocyanate 1-naphthyl ester 60mg/kg.Last administration fasting are after 16 hours, and femoral artery is collected blood, standing centrifugal, get serum, measure its total bilirubin (T-BIL) bilirubin direct (D-BIL), and calculate its indirect bilirubin level.The results are shown in Table 5.
Table 5 compound recipe Rhizoma Picrorhizae causes the impact (x ± s) of hepatic injury rat blood serum content of bilirubin on isothiocyanate 1-naphthyl ester
| Group | Dosage (g/kg) | N | T-Bil（IU/L） | D-Bil（U/L） | Indirectly-Bil(U/L) |
| Contrast | ? | 10 | 39.2±7.5 *** | 13.4±7.9 *** | 25.9±1.9*** |
| Model | ? | 10 | 468.1±68.4 | 427.6±61.4 | 40.5±10.9 |
| Medicine of the present invention | 2.0 | 10 | 306.7±81.1*** | 274.0±77.2 *** | 32.6±12.1 |
| Medicine of the present invention | 4.0 | 10 | 351.2±70.9*** | 311.1±66.6*** | 40.1±5.9 |
| Medicine of the present invention | 8.0 | 10 | 279.6±113.9*** | 242.2±110.5*** | 37.4±7.8 |
| Bicyclol | 0.1 | 10 | 523.8±90.5 | 476.8±71.6 | 52.9±17.2 |
With model group comparison:
* p<0.01, * * p<0.001.
From table 5, lumbar injection isothiocyanate 1-naphthyl ester causes rat blood serum T-Bil, D-Bil and indirectly-Bil value significantly raises, and relatively has significant difference with matched group.Compound recipe Rhizoma Picrorhizae can significantly reduce isothiocyanate 1-naphthyl ester rat blood serum T-Bil value and D-Bil, relatively has significant difference with model group.But unconjugated bilirubin is had no significant effect, with relatively no difference of science of statistics of model group.
Claims (12)
1. the pharmaceutical composition for the treatment of hepatic injury, it is characterized in that take the raw material of the active drug composition of weight portion as:
Rhizoma Picrorhizae 5-10 part, Flos Carthami 5-10 part, ZANGYINCHEN 1-5 part,
The sub-1-5 part of Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae 1-5 part.
2. compositions as claimed in claim 1, is characterized in that the raw material of described active drug composition is:
6 parts of Rhizoma Picrorhizae, 6 parts, Flos Carthami, 4.5 parts of ZANGYINCHEN,
3 parts of 1.5 parts of Fructus Chebulaes of Sophora moocroftiana(Wall．) Benth. Ex Bak..
3. compositions as claimed in claim 1 or 2, the water of the described each active drug composition raw material that it is characterized in that serving as reasons and/or ethanol extraction composition.
4. the medicine for the treatment of hepatic injury, is characterized in that take the pharmaceutical composition one of claims 1 to 3 Suo Shu as effective ingredient, jointly forms with acceptable auxiliary element in medicine.
5. the medicine for the treatment of hepatic injury as claimed in claim 4, is characterized in that for capsule, tablet, granule or pill medicine.
6. the preparation method of the described pharmaceutical composition of one of claims 1 to 3, after it is characterized in that the Rhizoma Picrorhizae in described raw material, ZANGYINCHEN, Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae to pulverize, after extracting with the alcoholic solution of volumetric concentration 50% ~ 80%, filter, filtrate is removed ethanol and is condensed into extractum, mixes with the water extraction concentrate of Flos Carthami.
7. preparation method as claimed in claim 6, filters after it is characterized in that extracting with the alcoholic solution of volumetric concentration 50% ~ 80%, and filtrate is removed ethanol and is condensed into extractum, mixes also further dry with the water extraction concentrate of Flos Carthami.
8. preparation method as claimed in claim 6, it is characterized in that described ethanol extraction for respectively with the described alcoholic solution reflux, extract, of 6 ~ 12 times at least 2 times, each 1 ~ 2 hour, merge the extracting solution of each time.
9. preparation method as claimed in claim 6, the Flos Carthami described in it is characterized in that uses respectively 40 ℃ ~ 70 ℃ warm macerating of water of 10 ~ 20 times of weight to extract at least 2 times.
10. the preparation method of the described pharmaceutical composition of one of claims 1 to 3, after it is characterized in that the Rhizoma Picrorhizae in described raw material, ZANGYINCHEN, Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae to pulverize, the alcoholic solution that is 50% ~ 80% by volumetric concentration in the lump with Flos Carthami extracts rear filtration, and filtrate is removed ethanol and is condensed into extractum.
11. preparation methoies of pharmaceutical composition as claimed in claim 10, filter after it is characterized in that extracting with the alcoholic solution of volumetric concentration 50% ~ 80%, and filtrate is removed ethanol and is condensed into extractum further dry.
The preparation method of one of 12. claims 1 to 3 described pharmaceutical composition, after it is characterized in that the Rhizoma Picrorhizae in described raw material, ZANGYINCHEN, Sophora moocroftiana(Wall．) Benth. Ex Bak., Fructus Chebulae to pulverize, mix with Flos Carthami, the water that adds respectively 10 ~ 15 times of weight at least decocts 2 times, each 1 ~ 2 hour, filter merging filtrate concentrate drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110309035.XA CN102327369B (en) | 2011-10-13 | 2011-10-13 | Pharmaceutical composition and medicine for treating hepatic injury, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110309035.XA CN102327369B (en) | 2011-10-13 | 2011-10-13 | Pharmaceutical composition and medicine for treating hepatic injury, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102327369A CN102327369A (en) | 2012-01-25 |
| CN102327369B true CN102327369B (en) | 2014-05-14 |
Family
ID=45479500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110309035.XA Expired - Fee Related CN102327369B (en) | 2011-10-13 | 2011-10-13 | Pharmaceutical composition and medicine for treating hepatic injury, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102327369B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920860B (en) * | 2012-11-29 | 2015-03-18 | 中央民族大学 | National medicinal composition for treating liver diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857605A (en) * | 2006-04-13 | 2006-11-08 | 孙成山 | Medicine for treating chronic alcoholic hepatopathy and its preparing method |
| CN1911045A (en) * | 2005-08-10 | 2007-02-14 | 兰州大学 | Bacteriostat and insecticide contg. extraction of silicicole pagoda-tree, and its prepn. method |
| CN101002860A (en) * | 2007-02-06 | 2007-07-25 | 李文良 | Oral medicine liquid for killing virus of hepatitis B, and its preparing method |
-
2011
- 2011-10-13 CN CN201110309035.XA patent/CN102327369B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911045A (en) * | 2005-08-10 | 2007-02-14 | 兰州大学 | Bacteriostat and insecticide contg. extraction of silicicole pagoda-tree, and its prepn. method |
| CN1857605A (en) * | 2006-04-13 | 2006-11-08 | 孙成山 | Medicine for treating chronic alcoholic hepatopathy and its preparing method |
| CN101002860A (en) * | 2007-02-06 | 2007-07-25 | 李文良 | Oral medicine liquid for killing virus of hepatitis B, and its preparing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102327369A (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN1286513C (en) | Chinese medicine composition for treating dermatosis and its preparing method | |
| CN101214288B (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation | |
| CN101143202A (en) | Compound oral administration preparation with protective function to chemical liver injury | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN101732668A (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN1250277C (en) | Medicine with antiphlogistic, analgetic, microbiostatic and diuretic effects | |
| CN1069542C (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN101342249B (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
| CN104474135A (en) | Pharmaceutical composition with auxiliary protection function of treating chemical liver injury | |
| CN103933195B (en) | A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine | |
| CN102327369B (en) | Pharmaceutical composition and medicine for treating hepatic injury, and preparation method thereof | |
| CN100333758C (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN101274034B (en) | Traditional Chinese medicine composition for relieving exterior syndrome, clearing heat and detoxicating | |
| CN100534520C (en) | Chinese medicine preparation for treating gynecologic inflammation | |
| CN105770579A (en) | Medicinal and edible homologous traditional Chinese medicine composition with liver-protecting effect | |
| CN102552806A (en) | Fat-burning dredging particles and preparation method thereof | |
| CN102114202A (en) | Liver-protecting composition and preparation method thereof | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN112316125B (en) | Traditional Chinese medicine composition based on hirudin and preparation method of micropills thereof | |
| CN104547945A (en) | Traditional Chinese medicine preparation for treating scrofula and preparation method of traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140514 Termination date: 20141013 |
|
| EXPY | Termination of patent right or utility model |